Mabion extended the scope of its cooperation with US Novavax to add another possible product to be produced by Mabion, namely Covid vaccine antigen for Omicron variant. The number of series of Omicron product will be agreed upon on the fly, with the manufacturing slots guaranteed to Novavax based on the contract between the two firms.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.09 USD | +3.54% | +3.02% | -14.79% |
Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
16.5 PLN | -0.12% | -2.94% | 65.87M | ||
4.09 USD | +3.54% | +3.02% | 572M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.79% | 572M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Mabion Announces Extension of Deal with Novavax